Request Information
Request Information
Nov 16 2017
Even when Auris Health, Inc., formerly known as Auris Surgical Robotics, was in stealth mode, it was featured as one of the new surgical robots about to enter the surgical suites. Dr. Fred Moll, CEO of Auris, is a well known as a pioneer in medical robotics. When Dr. Moll began developing the Monarch Platform, there was much speculation about his work. Lung cancer was identified as a key disease state that Auris was going to tackle.
Continue ReadingOct 27 2017
In this video interview at CHEST's Annual Meeting, Dr. Machuzak of the Cleveland Clinic summarizes his experience using the Monarch Platform in Auris's study, REACH Assessment: Advanced Bronchoscopic Techniques. According to Machuzak, Auris's robotic bronchoscope was compared to other standard flexible bronchoscopes, and the results were encouraging.
Continue ReadingAug 07 2017
Auris Health, formerly known as Auris Surgical Robotics, is featured in the article for raising an unprecedented amount of funding in 2017. According to this article, Auris raised $280 million in a Series D round. After raising a large investment, Auris has remained silent about its work on the Monarch Platform, creating great intrigue in the financial media.
Continue ReadingAug 04 2017
Auris is featured in this TechCrunch article not only for its impressive Series D funding but also for the opportunity it brings with its focus on the lung cancer market. Lung cancer claims more victims than prostate, breast, and colon cancer combined. It remains a very dangerous form of cancer because a diagnosis often comes late, when the cancer has already spread.
Continue ReadingAug 04 2017
Auris Health, formerly known as Auris Surgical Robotics, is featured in this article for its significant achievement in financing along with details surrounding its technology. Under the leadership of serial entrepreneur and Auris CEO, Dr. Fred Moll, Auris raised $280 million in a Series D round of financing. This was a generous amount to add to the existing $149.5 million from its Series C financing.
Continue ReadingAug 03 2017
Auris Health’s $280 million Series D financing made headlines in the Wall Street Journal. According to the article, the company’s financing is part of a significant increase in medical-technology venture funding. It also spoke of Auris CEO Dr. Fred Moll, a robotic-surgery pioneer and serial entrepreneur with much success from previous companies he founded.
Continue ReadingJul 17 2017
Auris joined the unicorn ranks in 2017 for reaching billion-dollar valuation. According to the article, 53 venture capital-backed companies reached billion-dollar valuations last year. Auris is the only company listed for robotics, medical robotics or endoscopy robotics.
Continue ReadingJan 23 2017
Even when Auris Health, Inc., formerly known as Auris Surgical Robotics, was in stealth mode, it was recognized as a fierce company, thanks to the innovation and experience of Auris CEO, Dr. Fred Moll. The serial entrepreneur and innovator has long contributed to the robotics space.
Continue ReadingJan 06 2017
Recent data showed the rise in robotics funding across various categories. According to the article, robotic startups had a record year in 2016 globally. Despite the majority of growth coming from the enterprise and consumer categories, the medical category saw an increase too. According to the article, Auris Health, Inc., formerly known as Auris Surgical Robotics, had the most funding for its robotic technology.
Continue ReadingAug 30 2016
This article featured Auris Health, formerly known as Auris Surgical Robotics, for how well-funded it is by venture capitalists. According to the article, one of Auris’s major investors, Lux Capital, made the list for most active VC investors in robotics from 2011 – 2016. Additionally, Auris ranked at the top for being the most-well funded robotics company from 2011 – 2016.
Continue ReadingBronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.